Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients

@article{Randall2001ParoxetineFS,
  title={Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients},
  author={Carrie L. Randall and Michael R. Johnson and Angelica K. Thevos and Susan C. Sonne and Suzanne Elizabeth Thomas and Shauna L. Willard and Kathleen T. Brady and Jonathan R. Davidson, M.D.},
  journal={Depression and Anxiety},
  year={2001},
  volume={14}
}
The objective of this study was to compare the efficacy and tolerability of paroxetine to matched placebo in adults with co‐occurring social anxiety disorder and alcohol use disorder. Outcome measures included standardized indices of social anxiety and alcohol use. Fifteen individuals meeting DSM‐IV criteria for both social anxiety disorder and alcohol use disorder were randomized to treatment. Paroxetine (n = 6) or placebo (n = 9) was given in a double‐blind format for 8 weeks using a flexible… Expand
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
TLDR
This study provides the first evidence-based recommendation for the use of an SSRI to treat social anxiety in this patient population by determining the efficacy of paroxetine in patients with co-occurring alcohol problems. Expand
A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?
TLDR
Successfully treating social anxiety symptoms with paroxetine does not reduce drinking in dual-diagnosed individuals who are not seeking treatment for alcohol problems, but paroxETine does reduce reliance on alcohol to engage in social situations, and may change the reasons why one drinks. Expand
Treating individuals with social anxiety disorder and at-risk drinking: phasing in a brief alcohol intervention following paroxetine.
TLDR
Paroxetine decreased social anxiety severity in the face of heavy drinking and decreasing the anxiety was related to a concurrent decrease in coping related drinking, and BI was not effective at decreasing drinking or drinking to cope. Expand
Levetiracetam for the Treatment of Co-Occurring Alcohol Dependence and Anxiety: Case Series and Review
  • J. Mariani, F. Levin
  • Psychology, Medicine
  • The American journal of drug and alcohol abuse
  • 2008
TLDR
Pre-clinical and clinical evidence suggests that levetiracetam, a newer generation anticonvulsant medication, may be efficacious in the treatment of co-occurring alcohol use and anxiety disorders. Expand
Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment
TLDR
Selective serotonin reuptake inhibitors (SSRIs), especially sertraline, showed effective results in posttraumatic stress disorder and in comorbid AnxD–AUD, and buspirone, gabapentin, and pregabalin were found to be effective in comorsical AnxDs–AUD. Expand
The impact of comorbid anxiety and depression on alcohol treatment outcomes.
TLDR
This study examines the impact of comorbid Diagnostic and Statistical Manual version IV (DSM-IV) anxiety and/or depression on out-patient treatment for alcohol problems and determines the most appropriate model of care for alcohol treatment seekers withComorbid DSM-IV anxiety and-or depression. Expand
Evidence-Based Pharmacotherapy for Mood and Anxiety Disorders with Concurrent Alcoholism
TLDR
Failure to treat a concurrent psychiatric disorder reduces the likelihood that the treatment for a substance use disorder (SUD) will be effective, and the effects of nontreatment were demonstrated in a prospective study assessing alcohol-dependent patients for 1 year following hospitalization for alcohol dependence. Expand
Pharmacotherapy for social anxiety disorder: a systematic review
TLDR
Taken together, trials of selective serotonin reuptake inhibitors and serotonin–norepinephrine reptake inhibitors provide the largest evidence base for agents that are both effective and well tolerated. Expand
Clinical practice guideline on pharmacological and psychological management of adult patients with an Anxiety Disorder and comorbid substance use.
This review synthesizes the pharmacological and psychosocial interventions that have been conducted in comorbid anxiety disorders and SUDs while also providing clinical recommendations about whichExpand
Pharmacotherapy for anxiety and comorbid alcohol use disorders.
TLDR
There was very low quality evidence for an effect of paroxetine on global clinical response to treatment, as assessed by the Clinical Global Impressions - Improvement scale (CGI-I). Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
TLDR
Paroxetine is an effective treatment for patients with generalized social phobia and short-term treatment results in substantial and clinically meaningful reductions in symptoms and disability. Expand
Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.
Sixty-five patients with social phobia were treated in a study that compared a cognitive-behavioral group treatment program with pharmacotherapy with alprazolam, phenelzine sulfate, or pill-placeboExpand
Treatment of social phobia with gabapentin: a placebo-controlled study.
TLDR
It seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia, and further studies are required to confirm this effect and to determine whether a dose-response relationship exists. Expand
Nefazodone in social phobia.
TLDR
Findings support a role for nefazodone in the treatment of social phobia, generalized type and controlled studies will be required to further investigate this preliminary finding. Expand
Cognitive behavioral therapy delays relapse in female socially phobic alcoholics.
TLDR
CBT is superior to Twelve-Step Facilitation therapy for the treatment of alcohol problems in specific populations, namely socially phobic women seeking outpatient treatment, and survival analyses revealed that female outpatients with social phobia showed delayed relapse to drinking when treated with CBT rather than TSF. Expand
Alcohol abuse and the anxiety disorders: Evidence from the epidemiologic catchment area survey
This study examined the prevalence of alcohol abuse and/or dependence in a sample of patients with anxiety disorders gathered from the Epidemiologic Catchment Area Study. Prior research had indicatedExpand
Anxiety disorders and alcoholism
Abstract Forty percent of a sample of 75 inpatient alcoholics received a lifetime diagnosis of one or more anxiety disorders. Phobic disorders were of comparable severity to those treated in phobiaExpand
Functional impairment in social phobia.
TLDR
Social phobia is associated with impairment in most areas of functioning, and the new scales appear useful in assessing functional impairment related to social phobia. Expand
Placebo-controlled trial of moclobemide in social phobia.
TLDR
Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small. Expand
Alcohol abuse in social phobia
Abstract Ninety-eight outpatients meeting DSM-III-R criteria for social phobia were evaluated for past history of RDC alcoholism using the SADS-LA structured interview. The resulting 16 subjects withExpand
...
1
2
3
4
...